_PVT_LTD.webp)
Libra Drugs (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 05-07-2024
- Paid Up Capital ₹ 1.99 M
as on 05-07-2024
- Company Age 32 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.11 M
as on 05-07-2024
- Revenue -39.41%
(FY 2021)
- Profit -100.29%
(FY 2021)
- Ebitda -71.44%
(FY 2021)
- Net Worth -0.20%
(FY 2021)
- Total Assets 3.85%
(FY 2021)
About Libra Drugs (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.99 M.
The company currently has active open charges totaling ₹1.11 M.
Umesh Parge, Abhay Parge, and Amar Rajaram serve as directors at the Company.
- CIN/LLPIN
U24232PN1992PTC068152
- Company No.
068152
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Libra Drugs (India) Pvt Ltd offer?
Libra Drugs (India) Pvt Ltd offers a wide range of products and services, including .
Who are the key members and board of directors at Libra Drugs (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amar Rajaram  | Managing Director | 12-Aug-1992 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umesh Parge | Director | 27-May-1994 | Current |
| Abhay Parge | Whole-Time Director | 23-Jan-2007 | Current |
Financial Performance of Libra Drugs (India).
Libra Drugs (India) Pvt Ltd, for the financial year ended 2021, experienced significant reduction in revenue, with a 39.41% decrease. The company also saw a substantial fall in profitability, with a 100.29% decrease in profit. The company's net worth dipped by a decrease of 0.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Libra Drugs (India)?
In 2021, Libra Drugs (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zusamen Lifesciences & Research Private LimitedActive 10 years 11 monthsUmesh Parge, Abhay Parge and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 26 Mar 2014 | ₹0.96 M | Open |
Bank Of India Creation Date: 03 Aug 2001 | ₹0.15 M | Open |
How Many Employees Work at Libra Drugs (India)?
Unlock and access historical data on people associated with Libra Drugs (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Libra Drugs (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Libra Drugs (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
